| All Releases |
|---|
 |
Peter Crowley Elected Progenics Chairman of the Board
Jun 10, 2010
|
13.4 KB
|
| |
TARRYTOWN, N.Y., Jun 10, 2010 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the
election of board member Peter J. Crowley as Chairman of the Board at
the Company's annual meeting. Mr. Crowley replaces Kurt Briner, who is
stepping down as Chairman at the end of his term while remaining a
...
|
|
|
Progenics Phase 1 PSMA ADC Study Presented in New "Trials in Progress" Poster Session at ASCO Annual Meeting
Jun 7, 2010
|
13.7 KB
|
| |
TARRYTOWN, N.Y. & CHICAGO, Jun 07, 2010 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today presented the
design and rationale of an ongoing phase 1 trial of its
prostate-specific membrane antigen antibody drug conjugate (PSMA ADC)
therapy at the 2010 Annual Meeting of the American Society of Clinical
...
|
|
|
Progenics Presents Novel Monoclonal Antibodies against Clostridium difficile at the American Society for Microbiology Conference
May 27, 2010
|
15.9 KB
|
| |
TARRYTOWN, N.Y. & SAN DIEGO, Calif., May 27, 2010 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the
presentation of preclinical data on novel monoclonal antibodies against
toxins produced by the bacterium Clostridium difficile (C.
difficile). The monoclonal antibodies effectively neutraliz...
|
|
|
Progenics Pharmaceuticals Announces First Quarter 2010 Financial Results
May 10, 2010
|
21.5 KB
|
| |
TARRYTOWN, N.Y., May 10, 2010 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its
results of operations for the quarter ended March 31, 2010.
Financial Results
Net loss for the first quarter of 2010 was $18.6 million or $0.58, basic
and diluted, per share, compared to $1.8 million or $0.06, basic ...
|
|
|
Progenics Announces Fourth Quarter and Year-End 2009 Financial Results
Mar 15, 2010
|
25.8 KB
|
| |
TARRYTOWN, N.Y., Mar 15, 2010 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its
results of operations for the fourth quarter and year ended December 31,
2009.
Financial Results
Net loss for the fourth quarter was $0.6 million or $0.02, basic and
diluted, per share, compared to $14.6 mill...
|
|
|
Progenics to Advance Oral Methylnaltrexone into Late Stage Clinical Development
Mar 12, 2010
|
16.6 KB
|
| |
TARRYTOWN, N.Y., Mar 12, 2010 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that it
plans to advance oral methylnaltrexone for the treatment of
opioid-induced constipation (OIC) into late stage clinical development
and will commence a phase 2b/3 clinical trial of a methylnaltrexone
...
|
|
|
Progenics Presents Novel Multiplex PI3-Kinase Inhibitors at American Association for Cancer Research Conference on Protein Translation and Cancer
Feb 4, 2010
|
15.8 KB
|
| |
TARRYTOWN, N.Y. & CORONADO, Calif., Feb 04, 2010 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the
presentation of preclinical data on a series of novel compounds that
simultaneously blocked two critical pathways involved in the growth and
survival of cancer cells. The compounds were ident...
|
|
|
CORRECTING and REPLACING Progenics Announces Third Quarter 2009 Financial Results
Nov 9, 2009
|
24.5 KB
|
| |
TARRYTOWN, N.Y., Nov 09, 2009 (BUSINESS WIRE) -- In the October Highlights section, the third sentence in the second
bullet should read xxx Significantly more patients on study drug
experienced laxation within two and four hours compared to those on
placebo (33% versus 0%, [p<0.05] and 39% versus 7%, [p<0.05],
respec...
|
|
|
Progenics Announces Third Quarter 2009 Financial Results
Nov 9, 2009
|
23.3 KB
|
| |
TARRYTOWN, N.Y., Nov 09, 2009 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its
results of operations for the third quarter and nine months ended
September 30, 2009.
Financial ResultsNet loss for the third quarter of 2009 was $13.0 million or $0.41, basic
and diluted, per share, compared ...
|
|
|
Progenics Regains Worldwide Rights to RELISTOR Franchise
Oct 14, 2009
|
22.6 KB
|
| |
TARRYTOWN, N.Y., Oct 14, 2009 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that it
has entered into an agreement with Wyeth Pharmaceuticals, a division of
Wyeth (NYSE: WYE) under which Progenics is regaining all worldwide
rights to the RELISTOR(R) franchise from Wyeth Pharmaceuticals,
...
|
|
|
Progenics Announces Promotion of Mark R. Baker to President and Appoints Him to Board of Directors
Sep 16, 2009
|
13.8 KB
|
| |
TARRYTOWN, N.Y., Sep 16, 2009 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the
promotion of Mark R. Baker to the newly created position of President.
Mr. Baker was also appointed to the Board of Directors. He will continue
to report to Paul J. Maddon, M.D., Ph.D., Progenics' Founder, Chie...
|
|
|
Progenics Announces Second Quarter 2009 Financial Results
Aug 6, 2009
|
19.3 KB
|
| |
TARRYTOWN, N.Y., Aug 06, 2009 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its
results of operations for the quarter and six months ended June 30, 2009.
Financial ResultsNet loss for the second quarter of 2009 was $15.2 million or $0.49,
basic and diluted, per share, compared to $2.4 million or ...
|
|
|
New Delivery System for RELISTOR in Pre-Filled Syringes Submitted for U.S. and European Marketing Approval
Aug 4, 2009
|
19.2 KB
|
| |
TARRYTOWN, N.Y. & COLLEGEVILLE, Pa., Aug 04, 2009 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) and Wyeth
Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced
submission of a supplemental New Drug Application (sNDA) to the United
States (U.S.) Food and Drug Administration (FDA) and an Extensi...
|
|
|
Progenics Announces Initiation of RELISTOR Clinical Trials in Japan by Ono Pharmaceutical
Jun 8, 2009
|
16.6 KB
|
| |
TARRYTOWN, N.Y., Jun 08, 2009 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that its
collaborator, Ono Pharmaceutical Co., Ltd., Osaka, Japan (OSE-TYO: 4528)
has begun clinical testing in Japan of RELISTOR(R)
(methylnaltrexone bromide) subcutaneous injection, the first-in-class
med...
|
|
|
Progenics Provides Update on Hepatitis C Program
Jun 8, 2009
|
13.1 KB
|
| |
TARRYTOWN, N.Y., Jun 08, 2009 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the
discontinuation of development for PRO 206, a pre-clinical compound for
the treatment of hepatitis C virus (HCV) infection. The decision was
made as part of a portfolio review, and is in line with the Company's...
|
|
|
Progenics Announces First Quarter Financial Results
May 11, 2009
|
21.3 KB
|
| |
TARRYTOWN, N.Y., May 11, 2009 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its
results of operations for the quarter ended March 31, 2009.
First Quarter Financial ResultsNet loss was $1.8 million or $0.06, basic and diluted, per share,
compared to $15.5 million or $0.52, basic and diluted, per s...
|
|
|
Phase 3 Clinical Study of RELISTOR Presented at American Pain Society Meeting Showed Positive Activity for the Treatment of Opioid-Induced Constipation in Chronic,Non-Cancer Pain Patients
May 7, 2009
|
22.7 KB
|
| |
COLLEGEVILLE, Pa. & TARRYTOWN, N.Y., May 07, 2009 (BUSINESS WIRE) -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics
Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced results from the
one-month, double-blind portion of a phase 3 trial of RELISTOR(R)
(methylnaltrexone bromide) subcutaneous injection t...
|
|
|
Progenics Pharmaceuticals Reports Fourth Quarter and Year-End Results and Corporate Update
Mar 13, 2009
|
23.6 KB
|
| |
TARRYTOWN, N.Y., Mar 13, 2009 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its
results of operations for the fourth quarter and year ended December 31,
2008.
Revenues for the fourth quarter totaled $6.8 million, compared to $15.5
million for the same period of 2007. For the year ended De...
|
|
|
Progenics Selects Subcutaneous Form of PRO 140, A Novel HIV Antibody Therapy, For Further Development
Feb 10, 2009
|
75.3 KB
|
| |
Montreal, Quebec and Tarrytown, NY - February 10, 2009 - Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that it has selected for further development the subcutaneous form of PRO 140 for the treatment of HIV infection. The decision follows positive results from a recently completed phase 2 clinical trial as well as feedbac...
|
|
|
Progenics Appoints Peter J. Crowley as Independent Board Member
Feb 4, 2009
|
13.2 KB
|
| |
TARRYTOWN, N.Y., Feb 04, 2009 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the
appointment of Peter J. Crowley to its Board of Directors as an
independent director. A senior healthcare investment banker with over 20
years' experience in the industry, Mr. Crowley will also serve on the
...
|
|
|
